Manufacturers’ views on outcome-based agreements

Introduction: utcome-based agreements (OBAs) are occasionally deployed to relieve the burden of high drug prices on healthcare budgets. However, it is not clear when manufacturers are willing to collaborate in establishing such agreements. Therefore, we explored the feasibility of OBAs from the manu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Lonneke Timmers, Anke Pisters-van Roy, Joël Gijzen, Nicole M.A. Blijlevens, Haiko Bloemendal
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	performance-based agreements outcome-based agreements market-access oncology drugs expensive drugs Public aspects of medicine RA1-1270 Business HF5001-6182
Acceso en línea:	https://doaj.org/article/2c82add5c86d4c679c4a8eb4cffafd74
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c82add5c86d4c679c4a8eb4cffafd74
record_format	dspace
spelling	oai:doaj.org-article:2c82add5c86d4c679c4a8eb4cffafd742021-11-11T14:23:42ZManufacturers’ views on outcome-based agreements2001-668910.1080/20016689.2021.1993593https://doaj.org/article/2c82add5c86d4c679c4a8eb4cffafd742021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/20016689.2021.1993593https://doaj.org/toc/2001-6689Introduction: utcome-based agreements (OBAs) are occasionally deployed to relieve the burden of high drug prices on healthcare budgets. However, it is not clear when manufacturers are willing to collaborate in establishing such agreements. Therefore, we explored the feasibility of OBAs from the manufacturer’s point of view. Methods: Dutch market-access experts from eight major pharmaceutical companies, globally active in the field of oncology, were interviewed. Opinions were compiled, and interviewees and their colleagues were then given the chance to review the manuscript for additional comments. Results: Most interviewees believe that OBAs can be useful in providing access to off-label use of authorised medicines, especially when no alternative treatment is available for seriously ill patients. For the licenced indications, manufacturers seem to be more inclined to collaborate when there is a potential incentive to improve market-access (e.g., if the product is not used because of concerns regarding its effectiveness). However, manufacturers are less likely to collaborate when there are greater financial risks for the company. Further concerns were definition of outcome or performance, the impact of compliance on the effectiveness of a drug, administrative burden, uncertainty regarding revenue recognition and the challenges of reimbursing combination therapies. Discussion: Market-access interviewees were generally positive about OBAs, however they were more reluctant towards OBAs for registered indications with low response-rate. The definition of performance or outcome and its clinical relevance and validity, the feasibility of OBAs and their administrative burden are relevant aspects that need to be addressed in advance. Ideally, countries should collaborate to share the outline of OBAs and create shared databases to accumulate evidence.Sahar Barjesteh van Waalwijk van Doorn-KhosrovaniLonneke TimmersAnke Pisters-van RoyJoël GijzenNicole M.A. BlijlevensHaiko BloemendalTaylor & Francis Grouparticleperformance-based agreementsoutcome-based agreementsmarket-accessoncology drugsexpensive drugsPublic aspects of medicineRA1-1270BusinessHF5001-6182ENJournal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	performance-based agreements outcome-based agreements market-access oncology drugs expensive drugs Public aspects of medicine RA1-1270 Business HF5001-6182
spellingShingle	performance-based agreements outcome-based agreements market-access oncology drugs expensive drugs Public aspects of medicine RA1-1270 Business HF5001-6182 Sahar Barjesteh van Waalwijk van Doorn-Khosrovani Lonneke Timmers Anke Pisters-van Roy Joël Gijzen Nicole M.A. Blijlevens Haiko Bloemendal Manufacturers’ views on outcome-based agreements
description	Introduction: utcome-based agreements (OBAs) are occasionally deployed to relieve the burden of high drug prices on healthcare budgets. However, it is not clear when manufacturers are willing to collaborate in establishing such agreements. Therefore, we explored the feasibility of OBAs from the manufacturer’s point of view. Methods: Dutch market-access experts from eight major pharmaceutical companies, globally active in the field of oncology, were interviewed. Opinions were compiled, and interviewees and their colleagues were then given the chance to review the manuscript for additional comments. Results: Most interviewees believe that OBAs can be useful in providing access to off-label use of authorised medicines, especially when no alternative treatment is available for seriously ill patients. For the licenced indications, manufacturers seem to be more inclined to collaborate when there is a potential incentive to improve market-access (e.g., if the product is not used because of concerns regarding its effectiveness). However, manufacturers are less likely to collaborate when there are greater financial risks for the company. Further concerns were definition of outcome or performance, the impact of compliance on the effectiveness of a drug, administrative burden, uncertainty regarding revenue recognition and the challenges of reimbursing combination therapies. Discussion: Market-access interviewees were generally positive about OBAs, however they were more reluctant towards OBAs for registered indications with low response-rate. The definition of performance or outcome and its clinical relevance and validity, the feasibility of OBAs and their administrative burden are relevant aspects that need to be addressed in advance. Ideally, countries should collaborate to share the outline of OBAs and create shared databases to accumulate evidence.
format	article
author	Sahar Barjesteh van Waalwijk van Doorn-Khosrovani Lonneke Timmers Anke Pisters-van Roy Joël Gijzen Nicole M.A. Blijlevens Haiko Bloemendal
author_facet	Sahar Barjesteh van Waalwijk van Doorn-Khosrovani Lonneke Timmers Anke Pisters-van Roy Joël Gijzen Nicole M.A. Blijlevens Haiko Bloemendal
author_sort	Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
title	Manufacturers’ views on outcome-based agreements
title_short	Manufacturers’ views on outcome-based agreements
title_full	Manufacturers’ views on outcome-based agreements
title_fullStr	Manufacturers’ views on outcome-based agreements
title_full_unstemmed	Manufacturers’ views on outcome-based agreements
title_sort	manufacturers’ views on outcome-based agreements
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/2c82add5c86d4c679c4a8eb4cffafd74
work_keys_str_mv	AT saharbarjestehvanwaalwijkvandoornkhosrovani manufacturersviewsonoutcomebasedagreements AT lonneketimmers manufacturersviewsonoutcomebasedagreements AT ankepistersvanroy manufacturersviewsonoutcomebasedagreements AT joelgijzen manufacturersviewsonoutcomebasedagreements AT nicolemablijlevens manufacturersviewsonoutcomebasedagreements AT haikobloemendal manufacturersviewsonoutcomebasedagreements
_version_	1718438922894180352

Manufacturers’ views on outcome-based agreements

Ejemplares similares